Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Hamburg – page 19

1 140 clinical trials in Hamburg, Germany across 19 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Hamburg at a glance
1 140
clinical trials
  • Research sites19
Type of trial
Recruitment status
Quick filters

1 140 trials in Hamburg

Open in trial search

Mantle cell lymphoma

Recruiting

Study of Glofitamab and Pirtobrutinib Treatment in Patients with Mantle Cell Lymphoma Who Have Failed Previous Therapy and in Previously Untreated Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:Klinikum der Universitaet Muenchen AöR

Acute myeloid leukaemia+3

Recruiting

Study comparing standard and reduced intensity treatment in patients with acute myeloid leukemia or chronic lymphocytic leukemia who have no detectable disease after initial therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan
  • Sponsor:Medizinische Hochschule Hannover

Acute lymphocytic leukaemia+1

Recruiting

Study of olverembatinib with chemotherapy versus standard therapy in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Ascentage Pharma Group Inc.

Diffuse large B-cell lymphoma+2

Recruiting

Study of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:Universitaet Muenster

Hodgkin's disease

Recruiting

Study of pembrolizumab with drug combination for first-line treatment in patients with advanced-stage classic Hodgkin lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Brentuximab Vedotin
  • Sponsor:University Of Cologne

Colorectal cancer metastatic+1

Recruiting

Study of melphalan followed by trifluridine-tipiracil and bevacizumab combination versus trifluridine-tipiracil and bevacizumab in liver metastatic colorectal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Delcath Systems Inc.

Breast cancer+1

Recruiting

Study of typology-based coaching and education to help patients with early hormone-positive HER2-negative breast cancer manage their treatment with ribociclib

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ribociclib
  • Sponsor:Institut fuer Frauengesundheit GmbH

Cholangiocarcinoma

Recruiting

Study of ivosidenib maintenance treatment in patients with IDH1-mutated cholangiocarcinoma after standard chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Triple negative breast cancer

Recruiting

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Colorectal cancer metastatic

Recruiting

Treatment with trastuzumab deruxtecan, capecitabine and bevacizumab for patients with HER2-positive metastatic colorectal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondazione GONO G.I.

IgA nephropathy

Recruiting

Study of felzartamab compared to placebo in adults with IgA nephropathy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Biogen Idec Research Limited

Dermatitis atopic

Recruiting

Study of GHZ339 for treatment of moderate to severe atopic dermatitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GHZ339
  • Sponsor:Novartis Pharma AG

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Hamburg

What the registry says about research in the country

01 Oncology Research

Current clinical trials focusing on innovative treatments for metastatic prostate cancer, colorectal cancer, and breast cancer. Studies are evaluating new therapeutic combinations and targeted approaches for improved patient outcomes.

  • Advanced cancer therapies
  • Immunotherapy combinations
  • Treatment resistance strategies
02 Infectious Disease Prevention

Comprehensive vaccine development programs targeting respiratory syncytial virus, cytomegalovirus, and meningococcal infections. Research focuses on both adult and pediatric populations.

  • Vaccine immunogenicity
  • Long-term protection
  • Novel vaccine platforms
03 Neurological Conditions

Groundbreaking research in treating acute cerebral ischemic stroke with innovative therapies. Studies are evaluating functional outcomes and safety profiles of new therapeutic agents.

  • Stroke treatment
  • Neuroprotective strategies
  • Recovery outcomes
04 Women's Health

Clinical investigations addressing vaginal atrophy and contraceptive technologies. Research includes novel delivery systems and hormone-based treatments for postmenopausal conditions.

  • Reproductive health
  • Hormone therapy
  • Novel delivery systems
Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.